Objective
The study aimed to synthesize and characterize pyrimidine-linked benzimidazole hybrids, define their antimicrobial and antifungal activities
in vitro
, and determine their ability to inhibit the main protease and spike glycoprotein of SARS-CoV-2.
Methods
The ability of the synthesized compounds to inhibit the main protease and spike glycoprotein inhibitory of SARS-CoV-2 was investigated by assessing their mode of binding to the allosteric site of the enzyme using molecular docking. The structures of pyrimidine-linked benzimidazole derivatives synthesized with microwave assistance were confirmed by spectral analysis. Antibacterial and antifungal activities were determined by broth dilution.
Results
Gram-negative bateria (
Escherichia coli
and
Pseudomonas aeruginosa
) were more sensitive than gram-positive bateria (
Staphylococcus aureus
and
Streptococcus pyogenes
) to the derivatives.
Candida albicans
was sensitive to the derivatives at a minimal inhibitory concentration (MIC) of 250 μg/mL. The novel derivatives had better binding affinity (kcal/mol) than nelfinavir, lopinavir, ivermectin, remdesivir, and favipiravir, which are under investigation as treatment for SARS-CoV-2 infection. Compounds 2c, 2e, and 2g formed four hydrogen bonds with the active cavity of the main protease. Many derivatives had good binding affinity for the RBD of the of SARS-CoV-2 spike glycoprotein with the formation of up to four hydrogen bonds.
Conclusion
We synthesized novel pyrimidine-linked benzi-midazole derivatives that were potent antimicrobial agents with ability to inhibit the SARS-CoV-2 spike glycoprotein. Understanding the pharmacophore features of the main protease and spike glycoprotein offers much scope for the development of more potent agents. We plan to optimize the properties of the derivatives using models
in vivo
and
in vitro
so that they will serve as more effective therapeutic options against bacterial and SARS-CoV-2 infections.
Objecive: A novel human coronavirus (HCoV), labelled as SARS-CoV-2 (COVID-19), causing pneumonia is spreading around the world. At present, there are no specific treatments for COVID-19. β-sitosterol is well known for its multiple biological actions. The aim of this research is to isolate and study binding affinity of β-sitosterol for SARS-CoV-2 (COVID-19) main protease (Mpro).
Methods: Extraction and Column chromatography was performed to isolate the β-sitosterol from n-hexane extract of Muntingia calabura bark followed by thin layer chromatography (TLC), HPTLC, FTIR and UV-Visible Spectroscopy. The molecular docking studies were performed on SARS-CoV-2 Mpro to determine the binding affinity of the β-sitosterol by using PyRx Virtual Screening Tool.
Results: In present study, preliminary phytochemical screening showed presence of carbohydrate, steroid, terpenoid and flavonoid compounds. Total 115 fractions were collected from column chromatography by using benzene as solvent by isocratic elution technique. HPTLC Fingerprinting analysis showed the presence of β-sitosterol under 366 nm. FTIR characterization was performed of the same fraction which clearly gives the absorption peaks which resembles to β-sitosterol structure.
Conclusion: The overall study concludes this method can be considered as a standard method for isolation of β-sitosterol from Muntingia calabura bark. Favipiravir have less binding affinity i.e. -5.7 kcal/mol than β-sitosterol which has -6.9 kcal/mol. The no. of hydrogen bonds formed by the Favipiravir is much more i.e. 04 than β-sitosterol which formed only 01 hydrogen bond with SARS-CoV-2 Mpro.
Purpose:
A new human coronavirus (SARS-CoV-2), triggering pneumonia is termed as Coronavirus Disease-19
(COVID-19). There is an alarming situation now as this new virus is spreading around the world. At present, there are no
specific treatments for COVID-19. Nigella sativa is known as Prophetic Medicine as its use has been mentioned in Prophetic
Hadith, as natural remedy for all the diseases except death. Seeds and oils of N. sativa have a long history of folklore usage
in various system of medicine such as Unani & Tibb, Ayurveda & Siddha in the treatment of different diseases and ailments.
The aim of this research is to provide potential inhibitor of SARS-CoV-2 Mpro
.
Method:
The Molecular docking tool was used to optimize the binding affinities of chemical constituents of N. sativa with
SARS-CoV-2 Mpro
.
Results:
Many constituents from N. Sativa have shown better binding affinity than reported drugs with SARS-CoV-2 Mpro
i.e. the alpha-hederin, Stigmasterol glucoside, Nigellidine-4-O-sulfite, Nigellidine, Sterol-3-β-D-glucoside, Dithymoquinone, beta-sitosterol have binding affinities (kcal/mol) -9, -8.1, -8, -7.7, -7.7, -7.4, -7.4, -6.9 and no. of hydrogen bonds
formed are 06, 04, 03, 03, 03, 00 and 01 respectively.
Conclusions:
There is rationale and pre-clinical evidence of effectiveness of N. Sativa that it may be helpful for the treatment
of COVID-19 and can serve as potential natural candidate. However, more studies should be conducted to collect high
quality data and scientific evidences of N. Sativa to use it against COVID-19 clinically.
One of the most significant challenges of diabetes health care is diabetic foot ulcers (DFU). DFUs are more challenging to cure, and this is particularly true for people who already have a compromised immune system. Pathogenic bacteria and fungi are becoming more resistant to antibiotics, so they may be unable to fight microbial infections at the wound site with the antibiotics we have now. This article discusses the dressings, topical antibacterial treatment, medications and debridement techniques used for DFU and provides a deep discussion of DFU and its associated problems. English-language publications on DFU were gathered from many different databases, such as Scopus, Web of Science, Science Direct, Springer Nature, and Google Scholar. For the treatment of DFU, a multidisciplinary approach involving the use of diagnostic equipment, skills, and experience is required. Preventing amputations starts with patient education and the implementation of new categorization systems. The microbiota involved in DFU can be better understood using novel diagnostic techniques, such as the 16S-ribosomal DNA sequence in bacteria. This could be achieved by using new biological and molecular treatments that have been shown to help prevent infections, to control local inflammation, and to improve the healing process.
Background:
COVID-19 (SARS-CoV-2 infection) has affected almost every region of the world. Presently, there is no defined line of treatment available for it. Triphala is already proven to have a safe biological window and well known for its antioxidant and immunomodulatory properties.
Objective:
Present work has been carried out to study Triphala's effectiveness for the treatment of COVID-19.
Methods:
The Receptor-binding domain (RBD) of SARS-CoV-2 Spike Glycoprotein responsible for the invasion into the host cell, which leads to further infection. The molecular docking (MD) was performed to explore the binding affinities (kcal/mol) of Triphala's chemical constituents and compared them with the existing drugs under investigation for the treatment of COVID-19 epidemiology.
Results:
Chebulinic acid binding affinity -8.5 kcal/mol with the formation of 10 hydrogen bonds. Almost all the major chemical constituents have formed two or more hydrogen bonds with RBD of SARS-CoV-2 Spike Glycoprotein.
Conclusion:
The present study showed that Triphala might perform vital roles in the treatment of COVID-19 and expand its usefulness to physicians to treat this illness. There is a need to complete the in-vitro, in-vivo biological testing of Triphala on SARS-CoV-2 disease to create more quality data. The binding mode of Chebulinic acid in the allosteric cavity allows a better understanding of RBD of SARS-CoV-2 Spike Glycoprotein target and provides insight for the design of new inhibitors. Triphala is already proven to have a safe biological window, which indicates we can skip the pre-clinical trials. Apart from this, Triphala is well known for its antioxidant properties, which ultimately improves the immunity of the COVID-19 patient.
Background:
Pneumonia induced by a novel coronavirus (SARS-CoV-2) was named as coronavirus disease 2019 (COVID-19). The Receptor-binding domain (RBD) of SARS-CoV-2 Spike Glycoprotein, causes invasion of the virus into the host cell by attaching with human angiotensin-converting enzyme-2 (hACE-2) which leads to further infection.
Objectives:
The novel N-(2-aminophenyl)-2,3-diphenylquinoxaline-6-sulfonamide derivatives were designed and synthesized to inhibit the RBD of SARS-CoV-2 Spike Glycoprotein by applying molecular docking tools.
Methods:
The synthesized products was characterized by Infrared Spectroscopy (IR), and 1H Nuclear Magnetic Resonance (NMR).
Results:
All the derivatives were found to have a very good binding affinity between -9 to -10.1 kcal/mol, better than the drugs which are under investigation for the treatment of SARS-CoV-2 infection. Compound F1 has formed 4 hydrogen bonds whereas, F4 and F10 formed two hydrogen bonds each with RBD of SARS-CoV-2 Spike Glycoprotein. All the derivatives were subjected to antimicrobial, antifungal, and antimalarial susceptibility.
Conclusion:
From the above-obtained results, we have concluded that novel N-(2-aminophenyl)-2,3-diphenylquinoxaline-6-sulfonamide derivatives have excellent potential to inhibit the receptor-binding domain (RBD) of SARS-CoV-2 Spike Glycoprotein, which is now an attentive target in designing SARS-CoV-2 inhibitors. This scaffold can hold an effective interest in the development of inhibitors for SARS-CoV-2 in the future if drug repurposing fails to serve the purpose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.